Edesa Biotech, Inc.
NASDAQ:EDSA · NASDAQ Capital Market
+$0.09 today
Vol 0.25M · Avg 0.62M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:EDSA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$10.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.35, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $119.3K -35.9% | $186.0K +1.4% | $183.5K +55.2% | $118.2K -0.5% | $118.8K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$119.3K +35.9% | -$186.0K -1.4% | -$183.5K -55.2% | -$118.2K +0.5% | -$118.8K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $3.7M +27.3% | $2.9M -39.9% | $4.8M -64.0% | $13.3M -25.7% | $17.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $4.2M +2.7% | $4.1M -6.7% | $4.4M -12.1% | $5.0M -12.2% | $5.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $7.8M +11.1% | $7.0M -23.9% | $9.2M -49.8% | $18.4M -22.4% | $23.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $119.3K -35.9% | $186.0K +1.4% | $183.5K +55.2% | $118.2K -0.5% | $118.8K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$7.1M -18.1% | -$6.0M +26.9% | -$8.2M +53.0% | -$17.4M -31.8% | -$13.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$7.9M -12.8% | -$7.0M +23.9% | -$9.2M +49.8% | -$18.4M +22.4% | -$23.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.6K -98.3% | $153.5K -47.0% | $289.8K +456185.1% | $64 -99.4% | $11.2K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $726.8K -14.0% | $845.5K -0.4% | $849.1K +3.2% | $822.7K -92.0% | $10.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$7.2M -16.5% | -$6.2M +26.3% | -$8.4M +52.3% | -$17.5M -31.5% | -$13.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $800 +0.0% | $800 +0.0% | $800 +0.0% | $800 +0.0% | $800 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$7.2M -16.5% | -$6.2M +26.3% | -$8.4M +52.3% | -$17.5M -31.5% | -$13.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +34.2% | -$2 +34.1% | -$3 +65.0% | -$8 -8.1% | -$8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +34.2% | -$2 +34.1% | -$3 +65.0% | -$8 -8.3% | -$8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $5.7M +77.5% | $3.2M +11.9% | $2.9M +36.4% | $2.1M +21.5% | $1.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $5.7M +77.5% | $3.2M +11.8% | $2.9M +36.4% | $2.1M +21.5% | $1.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Sensei Biotherapeutics, Inc.
SNSE
$18.59M
Cocrystal Pharma, Inc.
COCP
$10.09M
OSR Holdings, Inc.
OSRH
$9.43M
Traws Pharma, Inc.
TRAW
$7.01M
Immuron Limited
IMRN
$6.80M
Imunon, Inc.
IMNN
$4.77M
Evogene Ltd.
EVGN
$4.40M
BioRestorative Therapies, Inc.
BRTX
$3.54M
Dogwood Therapeutics, Inc.
DWTX
$2.81M
Ernexa Therapeutics Inc.
ERNA
$1.82M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EDSA generate?
Edesa Biotech, Inc. (EDSA) reported $0.00 of revenue in fiscal 2025.
Is EDSA profitable?
Edesa Biotech, Inc. (EDSA) reported -$7,185,523.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.